We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 0.05 | 0.15 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.27 | 453.89k |
From May 2019 to May 2024
TIDMBYOT
RNS Number : 7208Z
Byotrol PLC
04 September 2018
Byotrol plc
("Byotrol", the "Company" or the "Group")
Posting of Annual Report & Accounts and Notice of AGM
Byotrol plc, the AIM listed anti-microbial technology company, announces that it has posted to shareholders the Annual Report & Accounts for the year ended 31 March 2018 as well as a notice of the Annual General Meeting ('AGM').
The Company's AGM will be held at 10.30 am on Friday 21 September 2018 at the offices of finnCap Ltd, 60 New Broad Street, London EC2M 1JJ.
A copy of the Annual Report & Accounts and the notice of AGM is also available on the Company's website at http://byotrol.co.uk/investors/.
Enquiries:
David Traynor - Chief Executive, Byotrol plc 01925 742 000
David Paton - Investor Relations
07714 190 474
finnCap Ltd
020 7220 0500
(Nominated Adviser & Broker)
Geoff Nash/Kate Bannatyne - Corporate Finance
Tim Redfern/Richard Chambers - Corporate Broking
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.
Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NOASSSFSLFASESU
(END) Dow Jones Newswires
September 04, 2018 06:15 ET (10:15 GMT)
1 Year Byotrol Chart |
1 Month Byotrol Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
